Dutch Startup Sirius Medical Secures €10M Boost for Tumor Localization Tech

2025-02-06 bio

Eindhoven, Thursday, 6 February 2025.
Sirius Medical raised €10 million to advance their tumor localization tools, Sirius Pintuition and GPSDetect platforms, enhancing surgical precision and expanding into new markets.

Innovative Medical Technology for Cancer Surgery

Sirius Medical, a medtech startup founded in 2017 as a spin-off from the Netherlands Cancer Institute [1], has established itself as a leader in surgical tumor localization technology. Based in Eindhoven, the Netherlands, the company has developed the Sirius Pintuition system, a wire-free technology that employs magnetic seeds to help surgeons precisely locate and remove tumors [1][3]. The system has already proven its effectiveness, being implemented in over 250 centers worldwide and used in more than 35,000 procedures [1][3].

Strategic Investment for Global Growth

The funding round, announced on World Cancer Day 2025 [2], was led by Invest-NL and Nextgen Ventures, with additional support from De Groot Family Office and existing investors including the Brabant Development Agency (BOM), Holland Capital, Curie Capital, and Team Holmium [1][2][3]. According to Karin Steffens, senior investment manager at Invest-NL, ‘Sirius Medical’s mission to develop sustainable technology solutions while maintaining balance within the healthcare system closely aligns with our mission to accelerate the healthcare transition’ [1].

Revolutionary Approach to Cancer Surgery

The Sirius Pintuition system represents a significant advancement in surgical technology, offering a non-radioactive and wire-free solution for tumor localization [6]. This innovation is particularly crucial given that breast cancer affects 2.5 million people globally each year, many requiring surgery where tumors are often difficult to detect visually or by touch [6]. The technology provides surgeons with real-time audio and visual guidance through the Sirius Perception system, enhancing surgical precision [1].

Future Development and Market Expansion

CEO Bram Schermers emphasized that this funding milestone underscores the company’s commitment to improving cancer care globally [2]. The €10 million investment will be directed toward enhancing the Sirius Pintuition platform’s usability and intuitiveness, while also supporting expansion into new markets [1][3]. With both CE marking and FDA clearance already secured [1], Sirius Medical is well-positioned to continue its growth trajectory in the US, UK, EU countries, and Australia [2].

Bronnen

medtech innovation funding boost